Generation of Neural Stem Cells from AlphaSTEM™ Cultured Pluripotent Stem Cells
Patient-derived induced pluripotent stem cells (iPSCs) offer exciting potential for disease modeling, regenerative medicine, and therapeutic development. In order to fully realize the potential of iPSCs, it is critical to develop culture and differentiation methodologies that result in the most biologically relevant terminal cells (e.g. Neurons).
Minerva Biotechnologies is the first company to generate human naïve state induced pluripotent stem cells (iPSCs) using a single, naturally occurring human stem cell growth factor, NME7AB. Naïve stem cells have several advantages over current stem cells, called ‘primed’ state cells. Scientists believe that because these earlier stem cells have a “clean slate”, they are more easily directed to develop into functional mature cells. Using Minerva’s AlphaSTEM™ Culture System, differentiation efficiency is increased and the resulting cells have enhanced functionality.